Loading...
The availability of an effective vaccine to protect against infection with herpes simplex virus types 1 (HSV-1) and 2 (HSV-2) would have major public health implications. The results of two earlier trials that involved discordant couples in which one partner had recurrent HSV genital disease suggested that an HSV-2 glycoprotein D–based subunit (gD-2) vaccine provided significant protection against HSV-2 disease in the subset of women who were seronegative for both HSV-1 and HSV-2 antibodies. The current, partially manufacturer-sponsored investigation was conducted to evaluate the efficacy of the gD-2 vaccine in a larger group of HSV-1– and HSV-2–seronegative women.
More than 8000 women aged 18 to 30 from the U.S. and Canada participated in t…